COMPANY
Comanche Biopharma
Timeline
- Trial start Phase 1: A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months source ↗
- Trial start Early phase 1: Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects source ↗
Upcoming milestones
- Mar 31, 2027 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months · NCT07282171
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07282171 | A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months | Phase 1 | Recruiting | Feb 26, 2025 | Mar 31, 2027 (estimated) |
| NCT05881993 | Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects | Early phase 1 | Completed | May 22, 2023 | May 22, 2024 (actual) |
Raises and investors new
- InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗